

# Contents



1. Introduction	1
2. General policy	8
2.1 Collaboration with international organizations and agencies	8
2.2 Cross-cutting pharmaceuticals — quality assurance issues	13
2.3 Essential medicines for children	17
2.4 Counterfeit medicines	18
3. Quality control — specifications and tests	18
3.1 <i>The International Pharmacopoeia</i> (4th edition)	18
3.2 Proposed new work plan	18
3.3 Specifications for medicines, including children's medicines	19
3.4 Revision of texts	21
3.5 General monographs for dosage forms and associated method texts	21
3.6 Radiopharmaceuticals	25
3.7 Dissolution tests for addition to specific monographs	26
4. Quality control — International Chemical Reference Substances and International Infrared Reference Spectra	28
4.1 Annual report of the WHO Collaborating Centre	28
4.2 Adoption of new International Chemical Reference Substances	28
4.3 Infrared Reference Spectra	28
5. Quality control — national laboratories	29
5.1 External Quality Assurance Assessment Scheme	29
6. Quality assurance — good manufacturing practices	30
6.1 Good manufacturing practices for active pharmaceutical ingredients	30
6.2 Good manufacturing practices for biologicals	31
6.3 Good manufacturing practices — new texts	32
7. Quality assurance — new approaches and risk analysis	32
7.1 Technology transfer	33
8. Quality assurance — distribution and trade of pharmaceuticals	33
8.1 WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce	33
9. Quality assurance — stability	37
10. Prequalification of priority essential medicines and devices	38
10.1 Procedure for prequalification of medicines	38
10.2 Procedures for prequalification of intrauterine devices and condoms	39

11. Prequalification of active pharmaceutical ingredients	39
11.1 Procedure for prequalification of active pharmaceutical ingredients	39
12. Prequalification of quality control laboratories	40
13. Active pharmaceutical ingredient master file	41
14. Regulatory guidance	42
14.1 Specific guidance on children's medicines	42
14.2 Guidelines for pharmaceutical development of generics	42
14.3 Quality of herbal and complementary medicines	43
14.4 Near infrared spectroscopy	43
15. Nomenclature, terminology and databases	44
15.1 WHO terminology used in quality assurance	44
15.2 International Nonproprietary Names for pharmaceutical substances	44
15.3 Pharmacopoeial references	44
16. Miscellaneous	45
16.1 Diethylene glycol	45
16.2 Regulatory burden — inspections	45
17. Summary and recommendations	46
<b>Acknowledgements</b>	<b>53</b>
Annex 1	
List of available International Chemical Reference Substances and International Infrared Reference Spectra	59
Annex 2	
Procedure for assessing the acceptability, in principle, of male latex condoms for purchase by United Nations agencies	71
Annex 3	
Procedure for assessing the acceptability, in principle, of TCu380A intrauterine devices for purchase by United Nations agencies	87
Annex 4	
Guidelines on active pharmaceutical ingredient master file procedure	103
Annex 5	
International Nonproprietary Names for biological and biotechnological substances: a review	113